Anaplastic lymphoma kinase translocation is correlated with anaplastic lymphoma kinase expression and mutually exclusive with epidermal growth factor receptor mutation in Taiwanese non-small cell lung cancer

被引:2
|
作者
Hsu, Sheng-Chi [2 ]
Hung, Tsai-Hsien [3 ]
Wang, Chih-Wei [1 ]
Ng, Kwai-Fong [1 ]
Chen, Tse-Ching [1 ,2 ]
机构
[1] Chang Gung Univ, Chang Gung Mem Hosp, Sch Med, Dept Pathol, Taoyuan, Taiwan
[2] Chang Gung Mem Hosp, Canc Diagnost Lab, Taoyuan, Taiwan
[3] Chang Gung Univ, Coll Med, Grad Inst Biomed Sci, Div Biotechnol, Taoyuan, Taiwan
关键词
ALK; fluorescent in situ hybridization; molecular diagnosis; non-small cell lung cancer; EML4-ALK FUSION GENE; COPY NUMBER; ALK; REARRANGEMENT; GEFITINIB; EGFR; ADENOCARCINOMAS; RESPONSIVENESS; PATHOBIOLOGY; PATTERNS;
D O I
10.1111/pin.12268
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion gene is an important biomarker for target therapy. The aim of this study is to better understand the clinical and molecular features of the EML4-ALK fusion gene in lung cancer patients in Taiwan and therefore to generate an efficient algorithm for the detection of ALK translocation. In the first cohort, ALK translocation was identified in 1 adenocarcinoma from 100 lung cancer patients by using break apart fluorescent in situ hybridization (FISH). Next, we detected 6 ALK translocations in another 40 EGFR wild type adenocarcinomas but not in 40 cases with EGFR mutation. Histological analysis revealed that solid growth with signet-ring cells or cribriform glands with extracellular mucin were noted in all the 7 ALK translocated cases. One ALK positive cancer with mucinous cribriform pattern had no ALK expression. ALK expression was correlated with ALK translocation (p < 0.001), but not with ALK gene copy number gain (CNG) (P = 0.838). ALK translocation was also mutually exclusive with EGFR mutation in Taiwanese non-small cell lung cancer (P = 0.033). These results indicate that screening tests for EGFR mutation status and/or ALK expression could help efficiently select ALK translocated patients for target therapy.
引用
收藏
页码:231 / 239
页数:9
相关论文
共 50 条
  • [21] Epidermal growth factor receptor and anaplastic lymphoma kinase mutation in adenocarcinoma lung: Their incidence and correlation with histologic patterns
    Gupta, Pankaj
    Gowrishankar, Swarnalata
    Swain, Meenakshi
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2019, 62 (01) : 24 - 30
  • [22] Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
    Kwak, Eunice L.
    Bang, Yung-Jue
    Camidge, D. Ross
    Shaw, Alice T.
    Solomon, Benjamin
    Maki, Robert G.
    Ou, Sai-Hong I.
    Dezube, Bruce J.
    Jaenne, Pasi A.
    Costa, Daniel B.
    Varella-Garcia, Marileila
    Kim, Woo-Ho
    Lynch, Thomas J.
    Fidias, Panos
    Stubbs, Hannah
    Engelman, Jeffrey A.
    Sequist, Lecia V.
    Tan, WeiWei
    Gandhi, Leena
    Mino-Kenudson, Mari
    Wei, Greg C.
    Shreeve, S. Martin
    Ratain, Mark J.
    Settleman, Jeffrey
    Christensen, James G.
    Haber, Daniel A.
    Wilner, Keith
    Salgia, Ravi
    Shapiro, Geoffrey I.
    Clark, Jeffrey W.
    Iafrate, A. John
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18): : 1693 - 1703
  • [23] Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices
    Ess, S. M.
    Herrmann, C.
    Frick, H.
    Krapf, M.
    Cerny, T.
    Jochum, W.
    Frueh, M.
    EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (06)
  • [24] Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer
    Namrata Vijayvergia
    Ranee Mehra
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 437 - 446
  • [25] Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer
    Vijayvergia, Namrata
    Mehra, Ranee
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (03) : 437 - 446
  • [26] Alectinib in untreated anaplastic lymphoma kinase-positive non-small cell lung cancer
    Ruppert, Anne-Marie
    Mignard, Xavier
    Wislez, Marie
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (23)
  • [27] Targeting a cure in anaplastic lymphoma kinase-positive non-small cell lung cancer
    D'Amours, Marie-Frederique
    Ho, Cheryl
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (12) : 3815 - 3818
  • [28] Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer
    Yang, Junyi
    Gong, Weiliang
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (03) : 173 - 178
  • [29] Targeted degradation of anaplastic lymphoma kinase by target degraducer in non-small cell lung cancer
    Hwang, J. Y.
    Park, C-H.
    Lee, D. H.
    Kang, C. H.
    Lee, C. O.
    Ha, J. D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [30] Anaplastic lymphoma kinase inhibitors in elderly patients with advanced non-small cell lung cancer
    Zaarour, Mazen
    Nazha, Bassel
    Weerasinghe, Chanudi
    Moussaly, Elias
    Terjanian, Terenig
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (08) : 877 - 883